Cost effectiveness of a test to detect metastases for endometrial cancer

Gynecologic Oncology

Volumn 112, Issue 3, 2009, Pages 526-530

  Havrilesky, Laura J ^a,b   Maxwell, G Larry ^c,d,e   Chan, John K ^f,g,h   Myers, Evan R ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d United States Military Cancer Institute   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cost effectiveness; Diagnostic test; Endometrial cancer; Gynecologic Oncologist; Lymph node metastasis

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DATA BASE; DIAGNOSTIC TEST; ENDOMETRIUM CANCER; HEALTH CARE COST; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; PALLIATIVE THERAPY; PATIENT REFERRAL; PRIORITY JOURNAL; PROBABILITY; SALVAGE THERAPY;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIAGNOSTIC TECHNIQUES, OBSTETRICAL AND GYNECOLOGICAL; ENDOMETRIAL NEOPLASMS; FEMALE; HEALTH CARE COSTS; HUMANS; LYMPHATIC METASTASIS; MARKOV CHAINS; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY;

EID: 60549086764     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.11.017     Document Type: Article

References (19)

1. Onda T., Yoshikawa H., Mizutani K., Mishima M., Yokota H., Nagano H., et al. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br. J. Cancer. 75 (1997) 1836-1841
2. Bristow R.E., Zahurak M.L., Alexander C.J., Zellars R.C., and Montz F.J. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. Int. J. Gynecol. Cancer. 13 (2003) 664-672
3. Havrilesky L.J., Cragun J.M., Calingaert B., Synan I., Secord A.A., Soper J.T., et al. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol. Oncol. 99 (2005) 689-695
4. Bristow R.E., Zerbe M.J., Rosenshein N.B., Grumbine F.C., and Montz F.J. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol. Oncol. 78 (2000) 85-91
5. Cragun J, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, et-al., Therapeutic benefit of selective lymphadenectomy in apparent early stage endometrial cancer. Society of Gynecologic Oncologists 35th Annual Meeting, San Diego, CA 2004.
6. Chan J.K., Cheung M.K., Huh W.K., Osann K., Husain A., Teng N.N., et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 107 (2006) 1823-1830
7. Kilgore L.C., Partridge E.E., Alvarez R.D., Austin J.M., Shingleton H.M., Noojin III F., et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol. Oncol. 56 (1995) 29-33
8. Carney M.E., and WC. A population-based study of patterns of care for endometrial cancer. Who is seen by a Gynecologic Oncologist and who is not?. Gynecol. Oncol. 84 (2002) 479-536
9. Bidus M.A., Risinger J.I., Chandramouli G.V., Dainty L.A., Litzi T.J., Berchuck A., et al. Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray. Clin. Cancer Res. 12 (2006) 83-88
10. Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Graham J.E., and Heller P.B. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 60 (1987) 2035-2041
11. Chan J.K., Wu H., Cheung M.K., Shin J.Y., Osann K., and Kapp D.S. The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol. Oncol. 106 (2007) 282-288
12. Rankins N.C., Secord A.A., Jewell E., Havrilesky L.J., Soper J.T., and Myers E. Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer. Gynecol. Oncol. 106 (2007) 388-393
13. Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 22 (2004) 2159-2166
14. Havrilesky L.J., Alvarez Secord A., Darcy K.M., Armstrong D.K., and Kulasingam S. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J. Clin. Oncol. (2008) 26
15. Gold M.S.J., Russell L., and Weinstein M. Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, New York
16. Mariani A., Webb M.J., Keeney G.L., Haddock M.G., Calori G., and Podratz K.C. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?. Am. J. Obstet. Gynecol. 182 (2000) 1506-1519
17. Hricak H., Rubinstein L.V., Gherman G.M., and Karstaedt N. MR imaging evaluation of endometrial carcinoma: results of an NCI cooperative study. Radiology 179 (1991) 829-832
18. Connor J.P., Andrews J.I., Anderson B., and Buller R.E. Computed tomography in endometrial carcinoma. Obstet. Gynecol. 95 (2000) 692-696
19. Horowitz N.S., Dehdashti F., Herzog T.J., Rader J.S., Powell M.A., Gibb R.K., et al. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol. Oncol. 95 (2004) 546-551